SirPlux Duo
Phase 1- Indications
- Coronary artery disease, Peripheral artery disease
Company intelligence / Profile preview
Advanced NanoTherapies has completed preclinical studies and a first-in-human trial for its SirPlux Duo drug-coated balloon, showing positive results in vascular uptake and cellular retention. The company has received FDA Breakthrough Device Designation for its dual-drug DCB platform targeting small vessel coronary artery disease and is planning further U.S. early feasibility studies
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Advanced NanoTherapies.